In this paper,15Cr-ODS steels containing 0,1 wt%,2 wt%and 3 wt%Al element were fabricated by combining wet-milling and spark plasma sintering(SPS)methods.The microstructure and mechanical properties of ODS steel were ...In this paper,15Cr-ODS steels containing 0,1 wt%,2 wt%and 3 wt%Al element were fabricated by combining wet-milling and spark plasma sintering(SPS)methods.The microstructure and mechanical properties of ODS steel were investigated by XRD,SEM,TEM,EBSD and tensile tests.The results demonstrate that the Al addition significantly refines the particle precipitates in the Fe-Cr matrix,leading to the obvious refinement in grain size of matrix and the improvement of mechanical properties.The dispersion particles in ODS steels with Al addition are identified as Al2O3 and Y_(2)Ti_(2)O_(7)nanoparticles,which has a heterogeneous size distribution in the range of 5 nm to 300 nm.Increasing Al addition causes an obvious increase in tensile strength and a decline in elongation.The tensile strength and elongation of 15Cr-ODS steel containing 3 wt%Al are 775.3 MPa and 15.1%,respectively.The existence of Al element improves the corrosion resistance of materials.The ODS steel containing 2 wt%Al shows corrosion potential of 0.39 V and passivation current density of 2.61×10^(−3)A/cm^(2)(1.37 V).This work shows that Al-doped ODS steels prepared by wet-milling and SPS methods have a potential application in structural parts for nuclear system.展开更多
There have only been a few reports on lansoprazole-associated collagenous colitis. Colonic mucosa of collagenous colitis is known to be endoscopically normal. We present a case of collagenous colitis where the mucosa ...There have only been a few reports on lansoprazole-associated collagenous colitis. Colonic mucosa of collagenous colitis is known to be endoscopically normal. We present a case of collagenous colitis where the mucosa showed diffuse cloudiness mimicking ulcerative colitis. A 70-year-old woman developed watery diarrhea four to nine times a day. She had interstitial pneumonia at 67 and reflux esophagitis at 70 years. Lansoprazole 30 mg/d had been prescribed for reflux esophagitis for nearly 6 mo. Lansoprazole was withdrawn due to its possible side effect of diarrhea. Colonoscopy disclosed diffuse cloudiness of the mucosa which suggested ulcerative colitis. Consequently sulfasalazine 2 g/d was started. The patient's diarrhea dramatically disappeared on the following day. However, biopsy specimens showed subepithelial collagenous thickening and infi ltration of inflammatory cells in the lamina propria, confirming the diagnosis of collagenous colitis. One month after sulfasalazine therapy was initiated, colonoscopic and histological abnormalities resolved completely. Five months later the diarrhea recurred. The findings on colonoscopy and histology were the same as before, confirming a diagnosis of collagenous colitis relapse. We found that the patient had begun to take lansoprazole again 3 mo ahead of the recent diarrhea. Withdrawal of lansoprazole promptly resolved the diarrhea. Endoscopic and histological abnormalities were also completely resolved, similar to the first episode. Retrospectively, the date of commencement of sulfasalazine and discontinuation of lansoprazole in the first episode was found to be the same. We conclude that this patient had lansoprazole-associated collagenous colitis.展开更多
Objective： The relationship between apparent diffusion coefficient （ADC） and chemotherapy has been established. However, whether ADC could be considered as a measure for monitoring response to sorafenib in hepatoce...Objective： The relationship between apparent diffusion coefficient （ADC） and chemotherapy has been established. However, whether ADC could be considered as a measure for monitoring response to sorafenib in hepatocellular carcinoma （HCC） has not been demonstrated. This study was to investigate the ADC changes of ad- vanced HCC under sorafenib treatment. Methods： Athymic mice with HepG2 xenografts were allocated to two groups： control and sorafenib （40 mg/kg, bid）. T2 and diffusion images were acquired at each time point （0, 10, 14, and 18 d post-therapy）. Tumor volume and changes in ADC were calculated. Results： Tumor volumes on Days 10, 14, and 18 after treatment showed significant decreases in the sorafenib-treated group compared with the control. Pretreatment ADC values were not significantly different between the control and treated groups. A slow increase in ADC in the peripheral zone of tumors appeared in the treated group, which was significantly higher compared with the control group on Days 10, 14, and 18. In the central part of tumors on Day 10 after treatment, an increase in ADC appeared in the treated and control groups, the ADC of the control group being significantly lower compared with the treated tumors From Day 10 to Day 14, the ADC map showed a progressive decrease in the central region of tumors in the treated and control groups. However, this change is more significant in the treated groups. Conclusions： Early changes in mean ADC correlated with sorafenib treatment in HCC, which are promising indicators for predicting sorafenib response in this carcinoma.展开更多
基金Project(2020JJ2001)supported by Outstanding Youth Scientist Foundation of Hunan Province,ChinaProject(6142912200102)supported by Foundation for National Key Laboratory of Science and Technology on Highstrength Structural Materials,China。
文摘In this paper,15Cr-ODS steels containing 0,1 wt%,2 wt%and 3 wt%Al element were fabricated by combining wet-milling and spark plasma sintering(SPS)methods.The microstructure and mechanical properties of ODS steel were investigated by XRD,SEM,TEM,EBSD and tensile tests.The results demonstrate that the Al addition significantly refines the particle precipitates in the Fe-Cr matrix,leading to the obvious refinement in grain size of matrix and the improvement of mechanical properties.The dispersion particles in ODS steels with Al addition are identified as Al2O3 and Y_(2)Ti_(2)O_(7)nanoparticles,which has a heterogeneous size distribution in the range of 5 nm to 300 nm.Increasing Al addition causes an obvious increase in tensile strength and a decline in elongation.The tensile strength and elongation of 15Cr-ODS steel containing 3 wt%Al are 775.3 MPa and 15.1%,respectively.The existence of Al element improves the corrosion resistance of materials.The ODS steel containing 2 wt%Al shows corrosion potential of 0.39 V and passivation current density of 2.61×10^(−3)A/cm^(2)(1.37 V).This work shows that Al-doped ODS steels prepared by wet-milling and SPS methods have a potential application in structural parts for nuclear system.
文摘There have only been a few reports on lansoprazole-associated collagenous colitis. Colonic mucosa of collagenous colitis is known to be endoscopically normal. We present a case of collagenous colitis where the mucosa showed diffuse cloudiness mimicking ulcerative colitis. A 70-year-old woman developed watery diarrhea four to nine times a day. She had interstitial pneumonia at 67 and reflux esophagitis at 70 years. Lansoprazole 30 mg/d had been prescribed for reflux esophagitis for nearly 6 mo. Lansoprazole was withdrawn due to its possible side effect of diarrhea. Colonoscopy disclosed diffuse cloudiness of the mucosa which suggested ulcerative colitis. Consequently sulfasalazine 2 g/d was started. The patient's diarrhea dramatically disappeared on the following day. However, biopsy specimens showed subepithelial collagenous thickening and infi ltration of inflammatory cells in the lamina propria, confirming the diagnosis of collagenous colitis. One month after sulfasalazine therapy was initiated, colonoscopic and histological abnormalities resolved completely. Five months later the diarrhea recurred. The findings on colonoscopy and histology were the same as before, confirming a diagnosis of collagenous colitis relapse. We found that the patient had begun to take lansoprazole again 3 mo ahead of the recent diarrhea. Withdrawal of lansoprazole promptly resolved the diarrhea. Endoscopic and histological abnormalities were also completely resolved, similar to the first episode. Retrospectively, the date of commencement of sulfasalazine and discontinuation of lansoprazole in the first episode was found to be the same. We conclude that this patient had lansoprazole-associated collagenous colitis.
基金supported by the National Natural Science Foundation of China(No.81071960)the New Teacher Foundation of the Ministry of Education,China(No.20100101120129)the Zhejiang Provincial Medical Science Research Foundation(No.2010KYA064),China
文摘Objective： The relationship between apparent diffusion coefficient （ADC） and chemotherapy has been established. However, whether ADC could be considered as a measure for monitoring response to sorafenib in hepatocellular carcinoma （HCC） has not been demonstrated. This study was to investigate the ADC changes of ad- vanced HCC under sorafenib treatment. Methods： Athymic mice with HepG2 xenografts were allocated to two groups： control and sorafenib （40 mg/kg, bid）. T2 and diffusion images were acquired at each time point （0, 10, 14, and 18 d post-therapy）. Tumor volume and changes in ADC were calculated. Results： Tumor volumes on Days 10, 14, and 18 after treatment showed significant decreases in the sorafenib-treated group compared with the control. Pretreatment ADC values were not significantly different between the control and treated groups. A slow increase in ADC in the peripheral zone of tumors appeared in the treated group, which was significantly higher compared with the control group on Days 10, 14, and 18. In the central part of tumors on Day 10 after treatment, an increase in ADC appeared in the treated and control groups, the ADC of the control group being significantly lower compared with the treated tumors From Day 10 to Day 14, the ADC map showed a progressive decrease in the central region of tumors in the treated and control groups. However, this change is more significant in the treated groups. Conclusions： Early changes in mean ADC correlated with sorafenib treatment in HCC, which are promising indicators for predicting sorafenib response in this carcinoma.
